Analysis: Potential Upside for Iovance Biotherapeutics Stock with $32 Price Target
Thursday, 7 March 2024, 11:01
Key Developments for Iovance Biotherapeutics Stock
Analyst Joseph Pantginis anticipates Iovance shares reaching $32, a 91% increase from $17. Regulators cleared the company to resume LN-145 clinical trial for lung cancer therapy, indicating promising revenue growth.
Potential Revenue Growth and Market Expansion
- Analysts forecast $167 million sales in 2024 and $357 million in 2025
- LN-145 advancing in clinical trials may boost stock
In conclusion, Iovance Biotherapeutics presents growth opportunities despite risks, making it a consideration for investors.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.